{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T17:20:25Z","timestamp":1774891225409,"version":"3.50.1"},"reference-count":35,"publisher":"Becaris Publishing Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>This study conducted an indirect treatment comparison (ITC) of iptacopan, the first oral monotherapy targeting factor B, versus pegcetacoplan, a subcutaneous infusion targeting complement component 3, in patients with paroxysmal nocturnal hemoglobinuria (PNH) and residual anemia despite complement component 5 inhibitors (C5i). An unanchored matching adjusted ITC was performed, using phase III APPLY-PNH and PEGASUS studies, identified by a systematic literature review. The outcomes were: change from baseline (CfB) in hemoglobin (Hb), with and without post-transfusion data, CfB in lactate dehydrogenase (LDH), CfB in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score, transfusion avoidance, and serious adverse events. Two adjustment scenarios were analyzed: (A) baseline Hb, sex, transfusion history \u226412\u00a0months, and (B) scenario A plus reticulocyte count, baseline LDH and age. After matching and adjusting, baseline characteristics were similar across trials. Iptacopan showed greater Hb improvements than pegcetacoplan with post-transfusion data (mean difference \u2013 scenario A: 1.05\u00a0g\/dl; p\u00a0&lt;\u00a00.001, scenario B: 0.76\u00a0g\/dl; p\u00a0=\u00a00.018) and without (A: 1.31\u00a0g\/dl; p\u00a0&lt;\u00a00.001, B: 1.01\u00a0g\/dl; p\u00a0=\u00a00.014). Odds of transfusion avoidance were higher with iptacopan (A: odds ratio [OR]\u00a0=\u00a09.17, p\u00a0=\u00a00.013; B: OR\u00a0=\u00a012.71, p\u00a0=\u00a00.009). No significant difference was noted in CfB in LDH and FACIT-Fatigue score. These findings suggest that iptacopan may improve Hb levels and reduce transfusion dependency compared with pegcetacoplan in PNH patients with residual anemia despite C5i and must be interpreted in the context of ITCs.<\/jats:p>","DOI":"10.57264\/cer-2025-0167","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T07:49:51Z","timestamp":1773906591000},"source":"Crossref","is-referenced-by-count":0,"title":["Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and residual anemia despite C5 inhibitor treatment"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3180-3570","authenticated-orcid":false,"given":"Austin","family":"Kulasekararaj","sequence":"first","affiliation":[{"name":"King's College Hospital NHS, London, UK"},{"name":"National Institute for Health &amp; Care Research &amp; Wellcome King's Research Facility, London, UK"},{"name":"King's College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9047-4538","authenticated-orcid":false,"given":"Phillip","family":"Scheinberg","sequence":"additional","affiliation":[{"name":"Hospital A Benefic\u00eancia Portuguesa, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8612-7680","authenticated-orcid":false,"given":"Maria-Magdalena","family":"Balp","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4087-8802","authenticated-orcid":false,"given":"Olivier","family":"Somenzi","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5203-9797","authenticated-orcid":false,"given":"Anggie","family":"Wiyani","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals UK Ltd, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6634-3823","authenticated-orcid":false,"given":"Josefin","family":"Snellman","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2988-6506","authenticated-orcid":false,"given":"Sarah","family":"Walsh","sequence":"additional","affiliation":[{"name":"EVERSANA, Burlington, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2505-1405","authenticated-orcid":false,"given":"Katharina","family":"Pannagl","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals UK Ltd, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0685-069X","authenticated-orcid":false,"given":"Jason","family":"Steenkamp","sequence":"additional","affiliation":[{"name":"EVERSANA, Burlington, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6222-4753","authenticated-orcid":false,"given":"R\u00e9gis Peffault","family":"de Latour","sequence":"additional","affiliation":[{"name":"French R\u00e9f\u00e9rence Center for Aplastic Anemia &amp; Paroxysmal Nocturnal Hemoglobinuria, Paris, France"},{"name":"Assistance Publique H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"18","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","article-title":"Paroxysmal nocturnal hemoglobinuria","volume":"124","author":"Brodsky R","year":"2014","unstructured":"Brodsky R. Paroxysmal nocturnal hemoglobinuria. Blood 124(18), 2804\u20132811 (2014).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_8_4_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2017.28","article-title":"Paroxysmal nocturnal haemoglobinuria","volume":"3","author":"Hill A","year":"2017","unstructured":"Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat. Rev. Dis. Primers 3(1), 1\u201314 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"19","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199511093331904","article-title":"Natural history of paroxysmal nocturnal hemoglobinuria","volume":"333","author":"Hillmen P","year":"1995","unstructured":"Hillmen P, Lewis S, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 333(19), 1253\u20131258 (1995).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_8_6_2","unstructured":"Food and Drug Administration. Soliris. (2019)."},{"issue":"25","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly R","year":"2011","unstructured":"Kelly R, Hill A, Arnold L Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 117(25), 6786\u20136792 (2011).","journal-title":"Blood"},{"issue":"22","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1182\/blood.V128.22.2428.2428","article-title":"Immediate, complete, and sustained inhibition of C5 with ALXN1210 reduces complement-mediated hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH): interim analysis of a dose-escalation study","volume":"128","author":"Lee J-W","year":"2016","unstructured":"Lee J-W, Bachman ES, Aguzzi R Immediate, complete, and sustained inhibition of C5 with ALXN1210 reduces complement-mediated hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH): interim analysis of a dose-escalation study. Blood 128(22), 2428 (2016).","journal-title":"Blood"},{"issue":"6","key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Lee J","year":"2019","unstructured":"Lee J, Sicre de Fontbrune F, Wong Lee Lee L Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood 133(6), 530\u2013539 (2019).","journal-title":"Blood"},{"issue":"6","key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor\u2013experienced adult patients with PNH: the 302 study","volume":"133","author":"Kulasekararaj AG","year":"2019","unstructured":"Kulasekararaj AG, Hill A, Rottinghaus ST Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor\u2013experienced adult patients with PNH: the 302 study. Blood 133(6), 540\u2013549 (2019).","journal-title":"Blood"},{"issue":"6","key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria","volume":"350","author":"Hillmen P","year":"2004","unstructured":"Hillmen P, Hall C, Marsh JC Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 350(6), 552\u2013559 (2004).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fimmu.2019.01157","article-title":"Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT","volume":"10","author":"Risitano AM","year":"2019","unstructured":"Risitano AM, Marotta S, Ricci P Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT. Front. Immunol. 10, 1157 (2019).","journal-title":"Front. Immunol."},{"issue":"2","key":"e_1_3_8_13_2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00277-021-04715-5","article-title":"The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey","volume":"101","author":"Dingli D","year":"2022","unstructured":"Dingli D, Matos JE, Lehrhaupt K The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. Ann. Hematol. 101(2), 251\u2013263 (2022).","journal-title":"Ann. Hematol."},{"issue":"4","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/ejh.13816","article-title":"The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: patient-reported insights on symptoms and quality of life","volume":"109","author":"Panse J","year":"2022","unstructured":"Panse J, Sicre de Fontbrune F, Burmester P The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: patient-reported insights on symptoms and quality of life. Eur. J. Haematol. 109(4), 351\u2013363 (2022).","journal-title":"Eur. J. Haematol."},{"issue":"12","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen P","year":"2006","unstructured":"Hillmen P, Young NS, Schubert J The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 355(12), 1233\u20131243 (2006).","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1038\/s41409-021-01372-0","article-title":"Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study","volume":"56","author":"Debureaux P-E","year":"2021","unstructured":"Debureaux P-E, Kulasekararaj AG, Cacace F Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study. Bone Marrow Transplant. 56(10), 2600\u20132602 (2021).","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1080\/16078454.2022.2127630","article-title":"The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective","volume":"27","author":"Sicre de Fontbrune F","year":"2022","unstructured":"Sicre de Fontbrune F, Burmester P, Piggin M The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective. Hematology 27(1), 1140\u20131151 (2022).","journal-title":"Hematology"},{"key":"e_1_3_8_18_2","unstructured":"Food and Drug Administration. Empaveli highlights of prescribing information. (2023). Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215014s002lbl.pdf"},{"key":"e_1_3_8_19_2","unstructured":"European Medicines Agency. Aspaveli (pegcetacoplan) summary of product characteristics (SMPC). (2022). Last updated: 14 June 2022. Available from: Https:\/\/www.Ema.Europa.Eu\/en\/documents\/product-information\/aspaveli-epar-product-information_en.Pdf"},{"issue":"11","key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen P","year":"2021","unstructured":"Hillmen P, Szer J, Weitz I Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 384(11), 1028\u20131037 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1073\/pnas.1820892116","article-title":"Small-molecule factor B inhibitor for the treatment of complement-mediated diseases","volume":"116","author":"Schubart A","year":"2019","unstructured":"Schubart A, Anderson K, Mainolfi N Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc. Natl Acad. Sci. USA 116(16), 7926\u20137931 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"5","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/S2352-3026(21)00028-4","article-title":"Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, Phase II, proof-of-concept trial","volume":"8","author":"Risitano AM","year":"2021","unstructured":"Risitano AM, R\u00f6th A, Soret J Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, Phase II, proof-of-concept trial. Lancet Haematol. 8(5), e344\u2013e354 (2021).","journal-title":"Lancet Haematol."},{"key":"e_1_3_8_23_2","unstructured":"Food and Drug Administration. Fabhalta highlights of prescribing information. (2023). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218276s001lbl.pdf"},{"key":"e_1_3_8_24_2","unstructured":"European Medicines Agency. Fabhalta summary of product characteristics. (2023). Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fabhalta-epar-product-information_en.pdf"},{"issue":"11","key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa2308695","article-title":"Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria","volume":"390","author":"Peffault de Latour R","year":"2024","unstructured":"Peffault de Latour R, Roth A, Kulasekararaj A Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 390(11), 994\u20131008 (2024).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_8_26_2","volume-title":"NICE DSU TSD 18: Methods for population-adjusted indirect comparisons in submissions to NICE","author":"Phillippo D","year":"2016","unstructured":"Phillippo D, Ades T, Dias S NICE DSU TSD 18: Methods for population-adjusted indirect comparisons in submissions to NICE. NICE Decision Support Unit, UK (2016)."},{"key":"e_1_3_8_27_2","unstructured":"NICE. NICE Health Technology Evaluations: The Manual [PMG36]. 31 January 2023. Available from: https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/introduction-to-health-technology-evaluation"},{"issue":"3","key":"e_1_3_8_28_2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1017\/S0266462319000333","article-title":"Population adjustment methods for indirect comparisons: a review of national institute for health and care excellence technology appraisals","volume":"35","author":"Phillippo DM","year":"2019","unstructured":"Phillippo DM, Dias S, Elsada A, Ades A, Welton NJ. Population adjustment methods for indirect comparisons: a review of national institute for health and care excellence technology appraisals. Int. J. Technol. Assess. Health Care 35(3), 221\u2013228 (2019).","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"e_1_3_8_29_2","unstructured":"Higgins J Thomas J Chandler J Cochrane Handbook for Systematic Reviews of Interventions Version 6.3. (2022). Available from: http:\/\/www.training.cochrane.org\/handbook"},{"issue":"12","key":"e_1_3_8_30_2","doi-asserted-by":"crossref","first-page":"S624","DOI":"10.1016\/j.jval.2024.10.3133","article-title":"SA52 efficacy of clinical interventions in paroxysmal nocturnal hemoglobinuria patients previously treated with C5 inhibitors: a systematic literature review","volume":"27","author":"Munro I","year":"2024","unstructured":"Munro I, Shodimu V, Webb N SA52 efficacy of clinical interventions in paroxysmal nocturnal hemoglobinuria patients previously treated with C5 inhibitors: a systematic literature review. Value Health 27(12), S624 (2024).","journal-title":"Value Health"},{"key":"e_1_3_8_31_2","unstructured":"Novartis Pharmaceuticals. Study of efficacy and safety of twice daily oral LNP023 in adult PNH patients with residual anemia despite anti-C5 antibody treatment (APPLY-PNH). (2020). Available from: https:\/\/clinicaltrials.gov\/study\/NCT04558918?a=7"},{"key":"e_1_3_8_32_2","unstructured":"Apellis Pharmaceuticals Inc. Study to evaluate the efficacy and safety of APL-2 in patients with paroxysmal nocturnal hemoglobinuria (PNH). (2018). Available from: https:\/\/clinicaltrials.gov\/study\/NCT03500549"},{"issue":"6","key":"e_1_3_8_33_2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/jrsm.1511","article-title":"Methods for population adjustment with limited access to individual patient data: a review and simulation study","volume":"12","author":"Remiro-Azocar A","year":"2021","unstructured":"Remiro-Azocar A, Heath A, Baio G. Methods for population adjustment with limited access to individual patient data: a review and simulation study. Res. Synth. Methods 12(6), 750\u2013775 (2021).","journal-title":"Res. Synth. Methods"},{"issue":"6","key":"e_1_3_8_34_2","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch J","year":"2012","unstructured":"Signorovitch J, Sikirica V, Erder M Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 15(6), 940\u2013947 (2012).","journal-title":"Value Health"},{"key":"e_1_3_8_35_2","unstructured":"R Core Team. R: a language and environment for statistical computing. (2021). Available from: https:\/\/www.R-project.org\/"},{"key":"e_1_3_8_36_2","unstructured":"Hainmueller J. Ebal: entropy reweighting to create balanced samples. (2022). Available from: https:\/\/CRAN.R-project.org\/package=ebal"},{"issue":"2","key":"e_1_3_8_37_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/ejh.14422","article-title":"Anchored indirect treatment comparison finds comparable effects of pegcetacoplan and iptacopan in paroxysmal nocturnal haemoglobinuria","volume":"115","author":"de Latour RP","year":"2025","unstructured":"de Latour RP, Kulasekararaj A, Dingli D Anchored indirect treatment comparison finds comparable effects of pegcetacoplan and iptacopan in paroxysmal nocturnal haemoglobinuria. Eur. J. Haematol. 115(2), 125\u2013133 (2025).","journal-title":"Eur. J. Haematol."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T16:28:35Z","timestamp":1774888115000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.57264\/cer-2025-0167"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0167","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"article-number":"e250167"}}